Houston, TX – December 01, 2011 - - (BUSINESS WIRE) ----- Hybrid Pharmaceuticals, the Genomics Biotech Engineering Company Hybrid Media Reporting From The Texas Workforce Commission Meeting Houston TX Galleria
Texas is doing great things to help in The Creation of a Blueprint for a Breast Cancer Cure. The University of Texas M.D. Anderson Cancer Center and The Texas
Workforce Commission Skills
Development Fund are two Texas organizations that has the synergy to create a 100,00 Jobs according to Rose Conrad CEO of Hybrid GenNxeix when incorporating Nanoparticles and Semiconductor to the Drug Discovery Process.
Just this Week University of Texas M.D. Anderson Cancer Center is stocking up on scientists and plunging into the business of drug development, a major upgrade to areas that have lagged considerably behind the institution's clinical-care reputation.
The creation of the Institute for Applied Cancer Science, an effort aimed atconverting basic discoveries into new cancer therapies. The institute will be staffed by 28 scientists newly recruited from a similar initiative at the Harvard-affiliated Dana Farber Cancer Center. That initiative was co-founded and headed by Dr. Ronald DePinho, M.D. Anderson's new president.
"This will allow us to exploit opportunities provided by recent transformative technological and scientific advances and launch a biotech industry in Houston," said DePinho, who succeeded Dr. John Mendelsohn Sept. 1. "It should improve an
appallingly low rate of success in the current cancer drug pipeline.".
The Texas Workforce Commission Skills Development Fund is Texas' premier job–training program providing training dollars for Texas businesses and workers. Administered by the Texas Workforce Commission, success is achieved through collaboration among businesses, public Community and Technical colleges, Local Workforce Development Boards and economic development partners.
For the next two fiscal years (September 1, 2011 – August 31, 2013), TWC has $48 million in Skills Development Funds to support high quality, customized job training projects across the state. Grants for a single business may be limited to $500,000.
How does it work?
A business, consortium of businesses, or trade union identifies a training need, and then partners with a public Community or Technical college to fill its specific
needs. Businesses work with college partners to submit proposals, develop curricula and conduct training. The Skills Development Fund pays for the training, the college administers the grant, and businesses create new jobs and improve the skills of their current workers. How The Synergy would work:
GenNxeix scientist say photoluminescent nanoparticles will allow oncologists to discriminate between cancerous cells and healthy cells. Proteomics and bioinformatics will enable researchers to identify markers of Breast cancer susceptibility and precancerous lesions
Numerous investigations have shown that both tissue and cell distribution profiles of anticancer drugs can be controlled by their entrapment in submicronic colloidal systems (nanoparticles). The rationale behind this approach is to increase antitumor efficacy, while reducing systemic side-effects. This review provides an update of tumor targeting with conventional or long-circulating nanoparticles. The in vivo fate of these systems, after intravascular or tumoral administration, is discussed, as well as the mechanism involved in tumor regression. Nanoparticles are also of benefit for the selective delivery of oligonucleotides to tumor cells. Moreover, certain types of nanoparticles showed some interesting capacity to reverse MDR resistance, which is a major problem in chemotherapy. The first experiments, aiming to decorate nanoparticles with molecular ligand for active targeting of cancerous cells
Miniaturization will allow the tools for many different tests to be situated together on the same small device. Researchers hope that nanotechnology will allow them to run many diagnostic tests simultaneously.
Nanoparticles nanoshells is use to antibodies that recognize cancer cells. GenNxeix scientist envision letting these nanoshells seek out their cancerous targets, then applying near-infrared light. In laboratory cultures, the heat generated by the light-absorbing nanoshells can successfully killed breast cancer tumor cells while leaving neighboring cells intact.
A nanometer is a billionth of a meter. It's difficult to imagine anything so small, but think of something only 1/80,000 the width of a human hair. Ten hydrogen atoms could be laid side-by-side in a single nanometer.
GenNxeix minuscule molecule that will be used to detect breast cancer is a quantum dot. Quantum dots are tiny crystals that glow when they are stimulated by ultraviolet light. The wavelength, or color, of the light depends on the size of the crystal. Latex beads filled with these crystals can be designed to bind to specific DNA sequences.
GenNxeix scientists refer to these methods as the top-down approach and the bottom-up approach. The top-down approach involves molding or etching materials into smaller components. This approach has traditionally been used in making parts for
computers and electronics. The bottom-up approach involves assembling structures atom-by-atom or molecule-by-molecule, and may prove useful in manufacturing devices used in medicine. Get ready breast cancer science and information technology has breast cancer in the cross hairs
from different types of stress. Autophagy has been shown to play roles in normal physiological processes including energy metabolism, organelle turnover, growth regulation, and aging. Impaired breast autophagy leads to cancer. Autophagy has also been implicated in the cellular response to anti-breast cancer therapies.
anti-cancer therapy. Alteration of autophagy in endocrine therapy, chemotherapy and/or irradiation therapy is the nature tested. Evidence suggests that autophagy acts as a tumour suppressor and should be stimulated to decrease the incidence of cancer in breast cells. Analysing the reletionship between tumour suppression and autophagy genes in breast cancer.
As a result GenNxeix Scientist identified the tumour suppressive miRNA, miR-101, as a potent inhibitor of basal, etoposide- and rapamycin-induced autophagy. GenNxeix Scienyidt uses transcriptome to identified three novel miR-101 targets, ”STMN1″, ”RAB5A” and ”ATG4D”. where siRNA-depletion of these genes phenocopied the effect of miR-101overexpression, to demonstrating the genes importance in autophagy regulation. Importantly, overexpression of ”STMN1″could partially rescue cells from miR-101-mediated inhibition of autophagy. As a Result miR-101-mediated inhibition of autophagy will sensitize breast cancer cells to 4-hydroxytamoxifen mediated cell death. This is a classic case where genomics is here to stay.
